Recent studies have compared the efficacy and outcomes of key diabetes treatments including Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors, Glucagon-Like Peptide-1 (GLP-1) receptor agonists, and basal insulin formulations. Layton et al. investigated the differential impacts of SGLT2 and GLP-1 drugs on kidney disease and diabetes complications. Separately, a cross-national discrete choice experiment explored patient preferences for basal insulin across Canada, Spain, France, and Japan. These insights inform personalized therapeutic strategies in type 2 diabetes management.